Independent directory Public ClinicalTrials.gov records United States
ClinicalTrials.gov record
Completed Phase 3 Interventional Results available

Clinical Study Evaluating Safety and Efficacy of Fluticasone Furoate in People With Asthma

ClinicalTrials.gov ID: NCT01436071

Public ClinicalTrials.gov record NCT01436071. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Oct 28, 2026, 5:09 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Placebo-controlled (With Rescue Medication), Multi-centre Study to Evaluate the Efficacy and Safety of Inhaled Fluticasone Furoate in the Treatment of Persistent Asthma in Adults and Adolescents Not Currently Receiving Inhaled Corticosteroids

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

A randomised, double-blind, placebo-controlled (with rescue medication), multi-centre study to evaluate the efficacy and safety of inhaled fluticasone furoate in the treatment of persistent asthma in adults and adolescents not currently receiving inhaled corticosteroids

Study identification

NCT ID
NCT01436071
Recruitment status
Completed
Study type
Interventional
Phase
Phase 3
Lead sponsor
GlaxoSmithKline
Industry
Enrollment
248 participants

Conditions and interventions

Conditions

Interventions

Drug

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Sep 2011 (Type not available)
Primary completion
Jun 2012 (Actual)
Completion
Aug 2012 (Actual)
Last update posted
Jan 11, 2017

2011 – 2012

United States locations

U.S. sites
10
U.S. states
6
U.S. cities
10
Facility City State ZIP Site status
GSK Investigational Site Long Beach California 90808 —
GSK Investigational Site Los Angeles California 90025 —
GSK Investigational Site Newport Beach California 92663 —
GSK Investigational Site Albany Georgia 31707 —
GSK Investigational Site Columbia Missouri 65203 —
GSK Investigational Site Oklahoma City Oklahoma 73103 —
GSK Investigational Site Orangeburg South Carolina 29118 —
GSK Investigational Site Spartanburg South Carolina 29303 —
GSK Investigational Site Corsicana Texas 75110 —
GSK Investigational Site Waco Texas 76712 —

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 14 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT01436071, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 11, 2017 · Synced Oct 28, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT01436071 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →